Procept Biorobotics Company Insiders
| PRCT Stock | USD 57.92 0.26 0.45% |
Procept Biorobotics employs about 756 people. The company is managed by 12 executives with a total tenure of roughly 1764 years, averaging almost 147.0 years of service per executive, having 63.0 employees per reported executive. Breaking down Procept Biorobotics' management performance can provide insight into the firm performance.
Procept Biorobotics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1336) % which means that it has lost $0.1336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2762) %, meaning that it created substantial loss on money invested by shareholders. Procept Biorobotics' management efficiency ratios could be used to measure how well Procept Biorobotics manages its routine affairs as well as how well it operates its assets and liabilities.Procept Biorobotics Workforce Comparison
Procept Biorobotics Corp is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 12,936. Procept Biorobotics holds roughly 756 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.36) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.4) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.4. Procept Biorobotics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Procept Biorobotics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Procept Biorobotics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Procept Biorobotics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Procept Biorobotics Notable Stakeholders
A Procept Biorobotics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Procept Biorobotics often face trade-offs trying to please all of them. Procept Biorobotics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Procept Biorobotics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Reza Zadno | CEO President | Profile | |
| Kevin Waters | Executive CFO | Profile | |
| Matthew CFA | Vice Relations | Profile | |
| Christofer Christoforou | Senior Operations | Profile | |
| Hisham Shiblaq | Executive Officer | Profile | |
| Stacey Porter | Chief Officer | Profile | |
| Minni Vittal | VP Officer | Profile | |
| Alaleh Nouri | Chief EVP | Profile | |
| Mohan Sancheti | Senior Operations | Profile | |
| Thomas Yorkey | VP RD | Profile | |
| Bijesh Chandran | Senior Assurance | Profile | |
| Barry Templin | Executive Development | Profile |
About Procept Biorobotics Management Performance
The success or failure of an entity such as Procept Biorobotics Corp often depends on how effective the management is. Procept Biorobotics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Procept management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Procept management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. Procept Biorobotics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 234 people.
Please note, the imprecision that can be found in Procept Biorobotics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Procept Biorobotics Corp. Check Procept Biorobotics' Beneish M Score to see the likelihood of Procept Biorobotics' management manipulating its earnings.
Procept Biorobotics Workforce Analysis
Traditionally, organizations such as Procept Biorobotics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Procept Biorobotics within its industry.Procept Biorobotics Manpower Efficiency
Return on Procept Biorobotics Manpower
| Revenue Per Employee | 297K | |
| Revenue Per Executive | 18.7M | |
| Net Loss Per Employee | 120.9K | |
| Net Loss Per Executive | 7.6M | |
| Working Capital Per Employee | 567.1K | |
| Working Capital Per Executive | 35.7M |
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.